Monoclonal antibody directed against cROS, a proto-oncogene with therapeutic target potential.
| Inventor | Institute |
|---|---|
| Al Charest | Tufts University |
| Cat. #: | 151666 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell signaling and signal transduction;Genetics |
| Application: | IHC ; IF ; IP ; Fn ; WB |
| Target: | cROS |
| Reactivity: | Human |
| Clone: | 4-6G |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Monoclonal antibody directed against cROS, a proto-oncogene with therapeutic target potential. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Extracellular portion of ROS amino acid 1-285 fused to Fc, transiently expressed in 293 cells and purified using PtnA column chromatography. |
| Immunogen Uniprot ID: | P08922 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | c-ROS is a proto-oncogene tyrosine kinase, that is highly-expressed in a variety of tumour cell lines and belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. It is a type I integral membrane protein and may function as a growth or differentiation factor receptor. The c-ROS gene promoter region has been identified and characterized and it has been shown that the ectopic expression of c-ROS in tumours is tied to hypomethylation of a CpG island in the c-ROS promoter. Tumours with ROS1 mutations are typically responsive to small molecule tyrosine kinase inhibitors. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Fei et al. 2019. Biosci Rep. 39(6):. PMID: 31138757. Zhang et al. 2019. Int J Biol Sci. 15(7):1460-1471. PMID: 31337976. Shih et al. 2017. Oncogene. 36(47):6542-6554. PMID: 28759046. Deng et al. 2014. Int J Mol Med. 34(3):661-8. PMID: 24968753. Charest et al. 2003. Proc Natl Acad Sci U S A. 100(3):916-21. PMID: 12538861. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.